- Telehealth Visits
- Insurance plan information
James McCracken, MD
Psychiatry- Telehealth Visits
- Insurance plan information
James McCracken, MD
Psychiatry- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Child & Adolescent Psychiatry, American Board of Clinical Neuropsychology
- Psychiatry, American Board of Clinical Neuropsychology
Fellowship
- Child Psychiatry, UCLA School of Medicine - Department of Psychology
Internship
- Psychiatry, Duke University
Degree
- MD, Baylor College of Medicine
My expertise
Specialties
My research
Clinical trials
Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic StimulationOpens in a new window
Recruiting
Proportion (percentage) of all participants who enter the study, undergo a minimum of one TMS treatment, and complete the protocol-specified 15 TMS visitsExternal Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated SymptomsOpens in a new window
Recruiting
Examine the efficacy of external Trigeminal Nerve Stimulation (eTNS) in reducing ADHD symptoms as measured by the Attention-Deficit/Hyperactivity Disorder…
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.